J Dahm-Daphi1. 1. Department of Radiotherapy and Oncology, University of Hamburg, Germany. dahm@uke.uni-hamburg.de
Abstract
PURPOSE: p53 is the most commonly mutated gene in human tumors with large impact on cellular biology and response to radiation. Many excellent reviews are available on various aspects but for several years none about the role of p53 for radiosensitivity. The latter is the aim of the present paper. METHODS: Review of the literature. RESULTS: p53 is a regulator of apoptosis mainly in hematopoetic tissue. In normal tissue and solid tumors presumably other functions have more impact on the cellular response. p53 controls cell-cycle progression after irradiation and also DNA-repair, namely homologous and non-homologous recombination. Mutations of p53 alter these functions which may be responsible for an enhanced cellular and tumor radioresistance. At present only few reports were able to show that under tightly controlled conditions loss of p53 wild-type function leads to enhanced radioresistance. A general proof is still lacking. CONCLUSIONS: The emerging picture in the year 2000 shows p53 as a central protein in a multi-enzyme multi-function network which is far from being fully understood. Although p53 appears to be a major regulator it is certainly not the unreplaceable component the loss of which uniformly determines radioresistance. Only further understanding of modifiers and co-operators in the cell and in the specific tissue context will elucidate p53's role for radiosensitivity and radiotherapy.
PURPOSE:p53 is the most commonly mutated gene in humantumors with large impact on cellular biology and response to radiation. Many excellent reviews are available on various aspects but for several years none about the role of p53 for radiosensitivity. The latter is the aim of the present paper. METHODS: Review of the literature. RESULTS:p53 is a regulator of apoptosis mainly in hematopoetic tissue. In normal tissue and solid tumors presumably other functions have more impact on the cellular response. p53 controls cell-cycle progression after irradiation and also DNA-repair, namely homologous and non-homologous recombination. Mutations of p53 alter these functions which may be responsible for an enhanced cellular and tumor radioresistance. At present only few reports were able to show that under tightly controlled conditions loss of p53 wild-type function leads to enhanced radioresistance. A general proof is still lacking. CONCLUSIONS: The emerging picture in the year 2000 shows p53 as a central protein in a multi-enzyme multi-function network which is far from being fully understood. Although p53 appears to be a major regulator it is certainly not the unreplaceable component the loss of which uniformly determines radioresistance. Only further understanding of modifiers and co-operators in the cell and in the specific tissue context will elucidate p53's role for radiosensitivity and radiotherapy.
Authors: Peter L Roberson; Lauren B Smith; Meredith A Morgan; Matthew J Schipper; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja Journal: Cancer Biother Radiopharm Date: 2017-10-30 Impact factor: 3.099
Authors: B Pajares; L Perez-Villa; J M Trigo; M D Toledo; M Alvarez; B Jimenez; J A Medina; V de Luque; J M Jerez; E Alba Journal: Clin Transl Oncol Date: 2013-11-06 Impact factor: 3.405
Authors: Bianca M Sirbu; Sarah J Lachmayer; Verena Wülfing; Lara M Marten; Katie E Clarkson; Linda W Lee; Liliana Gheorghiu; Lee Zou; Simon N Powell; Jochen Dahm-Daphi; Henning Willers Journal: PLoS One Date: 2011-08-12 Impact factor: 3.240
Authors: Nataliya Zhukova; Vijay Ramaswamy; Marc Remke; Dianna C Martin; Pedro Castelo-Branco; Cindy H Zhang; Michael Fraser; Ken Tse; Raymond Poon; David J H Shih; Berivan Baskin; Peter N Ray; Eric Bouffet; Peter Dirks; Andre O von Bueren; Elke Pfaff; Andrey Korshunov; David T W Jones; Paul A Northcott; Marcel Kool; Trevor J Pugh; Scott L Pomeroy; Yoon-Jae Cho; Torsten Pietsch; Marco Gessi; Stefan Rutkowski; Laszlo Bognár; Byung-Kyu Cho; Charles G Eberhart; Cecile Faure Conter; Maryam Fouladi; Pim J French; Wieslawa A Grajkowska; Nalin Gupta; Peter Hauser; Nada Jabado; Alexandre Vasiljevic; Shin Jung; Seung-Ki Kim; Almos Klekner; Toshihiro Kumabe; Boleslaw Lach; Jeffrey R Leonard; Linda M Liau; Luca Massimi; Ian F Pollack; Young Shin Ra; Joshua B Rubin; Erwin G Van Meir; Kyu-Chang Wang; William A Weiss; Karel Zitterbart; Robert G Bristow; Benjamin Alman; Cynthia E Hawkins; David Malkin; Steven C Clifford; Stefan M Pfister; Michael D Taylor; Uri Tabori Journal: Acta Neuropathol Commun Date: 2014-12-24 Impact factor: 7.801
Authors: Bella Pajares; Jose M Trigo; Maria D Toledo; Martina Álvarez; Carlos González-Hermoso; Antonio Rueda; Jose A Medina; Vanessa de Luque; Jose M Jerez; Emilio Alba Journal: BMC Cancer Date: 2013-01-18 Impact factor: 4.430